Substituted pyrazole and triazole compounds as KSP inhibitors

Details for Australian Patent Application No. 2007323998 (hide)

Owner Novartis AG

Inventors Mendenhall, Kris G.; Barsanti, Paul A.; Duhl, David; Walter, Annette O.; Renhowe, Paul A.; Xia, Yi

Agent Davies Collison Cave

Pub. Number AU-B-2007323998

PCT Pub. Number WO2008/063912

Priority 60/858,964 13.11.06 US

Filing date 8 November 2007

Wipo publication date 29 May 2008

Acceptance publication date 22 September 2011

International Classifications

C07D 249/08 (2006.01) Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61P 35/00 (2006.01) Antineoplastic agents

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

28 May 2009 PCT application entered the National Phase

  PCT publication WO2008/063912 Priority application(s): WO2008/063912

22 September 2011 Application Accepted

  Published as AU-B-2007323998

19 January 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007323999-Asphalt shingle coating with improved tear strength

2007323996-Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions